[1]
|
Bonser, L.R. and Erle, D.J. (2017) Airway Mucus and Asthma: The Role of MUC5AC and MUC5B. Journal of Clinical Medicine, 6, Article No. 112. https://doi.org/10.3390/jcm6120112
|
[2]
|
Peljto, A.L., Zhang, Y., Fingerlin, T.E., Ma, S.-F., Garcia, J.G.N., Richards, T.J., Silveira, L.J., Lindell, K.O., Steele, M.P., Loyd, J.E., Gibson, K.F., Seibold, M.A., Brown, K.K., Talbert, J.L., Markin, C., Kossen, K., Seiwert, S.D., Murphy, E., Noth, I., Schwarz, M.I., Kaminski, N. and Schwartz, D.A. (2013) Association between the MUC5B Promoter Polymorphism and Survival in Patients with Id-iopathic Pulmonary Fibrosis. JAMA, 309, 2232-2239.
https://doi.org/10.1001/jama.2013.5827
|
[3]
|
Seibold, M.A., Wise, A.L., Speer, M.C., Steele, M.P., Brown, K.K., Loyd, J.E., Fingerlin, T.E., Zhang, W., Gudmundsson, G., Groshong, S.D., Evans, C.M., Garantziotis, S., Adler, K.B., Dickey, B.F., du Bois, R.M., Yang, I.V., Herron, A., Kervitsky, D., Talbert, J.L., Markin, C., Park, J., Crews, A.L., Slifer, S.H., Auerbach, S., Roy, M.G., Lin, J., Hennessy, C.E., Schwarz, M.I. and Schwartz, D.A. (2011) A Common MUC5B Promoter Polymorphism and Pulmonary Fibrosis. The New England Journal of Medicine, 364, 1503-1512. https://doi.org/10.1056/NEJMoa1013660
|
[4]
|
Jiang, H., Hu, Y., Shang, L., Li, Y., Yang, L. and Chen, Y. (2015) Association between MUC5B Polymorphism and Susceptibility and Severity of Idiopathic Pulmonary Fibrosis. Interna-tional Journal of Clinical and Experimental Pathology, 8, 14953-14958.
|
[5]
|
Samara, K.D., Antoniou, K.M., Karagian-nis, K., Margaritopoulos, G., Lasithiotaki, I., Koutala, E. and Siafakas, N.M. (2012) Expression Profiles of Toll-Like Receptors in Non-Small Cell Lung Cancer and Idiopathic Pulmonary Fibrosis. International Journal of Oncology, 40, 1397-1404. https://doi.org/10.3892/ijo.2012.1374
|
[6]
|
O'Dwyer, D.N., Armstrong, M.E., Kooblall, M. and Don-nelly, S.C. (2015) Targeting Defective Toll-Like Receptor-3 Function and Idiopathic Pulmonary Fibrosis. Expert Opinion on Therapeutic Targets, 19, 507-514.
https://doi.org/10.1517/14728222.2014.988706
|
[7]
|
O'Dwyer, D.N., Armstrong, M.E., Trujillo, G., Cooke, G., Keane, M.P., Fallon, P.G., Simpson, A.J., Millar, A.B., McGrath, E.E., Whyte, M.K., Hirani, N., Hogaboam, C.M. and Donnelly, S.C. (2013) The Toll-Like Receptor 3 L412F Polymorphism and Disease Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 188, 1442-1450. https://doi.org/10.1164/rccm.201304-0760OC
|
[8]
|
McElroy, A.N., Invernizzi, R., Laskowska, J.W., O'Neill, A., Doroudian, M., Moghoofei, M., Mostafaei, S., Li, F., Przybylski, A.A., O'Dwyer, D.N., Bowie, A.G., Fallon, P.G., Maher, T.M., Hogaboam, C.M., Molyneaux, P.L., Hirani, N., Armstrong, M.E. and Donnelly, S.C. (2022) Candidate Role for Toll-Like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibro-sis. American Journal of Respiratory and Critical Care Medicine, 205, 550-562. https://doi.org/10.1164/rccm.202010-3880OC
|
[9]
|
Stewart, J.A., Chaiken, M.F., Wang, F. and Price, C.M. (2012) Maintaining the End: Roles of Telomere Proteins in End-Protection, Telomere Replication and Length Regulation. Muta-tion Research, 730, 12-19.
https://doi.org/10.1016/j.mrfmmm.2011.08.011
|
[10]
|
Borie, R., Tabèze, L., Thabut, G., Nunes, H., Cottin, V., Marchand-Adam, S., Prevot, G., Tazi, A., Cadranel, J., Mal, H., Wemeau-Stervinou, L., Bergeron Lafaurie, A., Isra-el-Biet, D., Picard, C., Reynaud Gaubert, M., Jouneau, S., Naccache, J.-M., Mankikian, J., Ménard, C., Cordier, J.-F., Valeyre, D., Reocreux, M., Grandchamp, B., Revy, P., Kannengiesser, C. and Crestani, B. (2016) Prevalence and Char-acteristics of TERT and TERC Mutations in Suspected Genetic Pulmonary Fibrosis. The European Respiratory Journal, 48, 1721-1731. https://doi.org/10.1183/13993003.02115-2015
|
[11]
|
Alder, J.K., Chen, J.J.L., Lancaster, L., Danoff, S., Su, S.-c., Cogan, J.D., Vulto, I., Xie, M., Qi, X., Tuder, R.M., Phillips, J.A., Lansdorp, P.M., Loyd, J.E. and Ar-manios, M.Y. (2008) Short Telomeres Are a Risk Factor for Idiopathic Pulmonary Fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 105, 13051- 13056. https://doi.org/10.1073/pnas.0804280105
|
[12]
|
Armanios, M. (2013) Telomeres and Age-Related Disease: How Telomere Biology Informs Clinical Paradigms. The Journal of Clinical Investigation, 123, 996-1002. https://doi.org/10.1172/JCI66370
|
[13]
|
Dai, J., Cai, H., Zhuang, Y., Wu, Y., Min, H., Li, J., Shi, Y., Gao, Q. and Yi, L. (2015) Telomerase Gene Mutations and Telomere Length Shortening in Patients with Idiopathic Pulmonary Fibro-sis in a Chinese Population. Respirology (Carlton, Vic.), 20, 122-128. https://doi.org/10.1111/resp.12422
|
[14]
|
Dai, J., Cai, H., Li, H., Zhuang, Y., Min, H., Wen, Y., Yang, J., Gao, Q., Shi, Y. and Yi, L. (2015) Association between Te-lomere Length and Survival in Patients with Idiopathic Pulmonary Fibrosis. Respirology (Carlton, Vic.), 20, 947-952.
https://doi.org/10.1111/resp.12566
|
[15]
|
Hisata, S., Kimura, Y., Shibata, N., Ono, S., Kobayashi, T., Chiba, S., Ohta, H., Nukiwa, T. and Ebina, M. (2011) A Normal Range of KL-6/MUC1 Independent of Elevated SP-D Indicates a Better Prognosis in the Patients with Honeycombing on High-Resolution Computed Tomography. Pulmonary Medicine, 2011, Article ID: 806014.
https://doi.org/10.1155/2011/806014
|
[16]
|
Satoh, H., Kurishima, K., Ishikawa, H. and Ohtsuka, M. (2006) In-creased Levels of KL-6 and Subsequent Mortality in Patients with Interstitial Lung Diseases. Journal of Internal Medi-cine, 260, 429-434.
https://doi.org/10.1111/j.1365-2796.2006.01704.x
|
[17]
|
Okamoto, T., Fujii, M., Furusawa, H., Tsuchiya, K., Miyazaki, Y. and Inase, N. (2015) The Usefulness of KL-6 and SP-D for the Diagnosis and Management of Chronic Hypersensitivity Pneumonitis. Respiratory Medicine, 109, 1576- 1581. https://doi.org/10.1016/j.rmed.2015.10.005
|
[18]
|
Xu, L., Bian, W., Gu, X.-H. and Shen, C. (2017) Differing Ex-pression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis. COPD, 14, 245-250.
https://doi.org/10.1080/15412555.2017.1278753
|
[19]
|
Hamai, K., Iwamoto, H., Ishikawa, N., Horimasu, Y., Ma-suda, T., Miyamoto, S., Nakashima, T., Ohshimo, S., Fujitaka, K., Hamada, H., Hattori, N. and Kohno, N. (2016) Com-parative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fi-brosis. Disease Markers, 2016, Article ID: 4759040.
https://doi.org/10.1155/2016/4759040
|
[20]
|
Yokoyama, A., Kondo, K., Nakajima, M., Matsushima, T., Takahashi, T., Nishimura, M., Bando, M., Sugiyama, Y., Totani, Y., Ishizaki, T., Ichiyasu, H., Suga, M., Hamada, H. and Kohno, N. (2006) Prognostic Value of Circulating KL-6 in Idiopathic Pulmonary Fibrosis. Respirology (Carlton, Vic.), 11, 164-168.
https://doi.org/10.1111/j.1440-1843.2006.00834.x
|
[21]
|
Sokai, A., Tanizawa, K., Handa, T., Kanatani, K., Kubo, T., Ikezoe, K., Nakatsuka, Y., Tokuda, S., Oga, T., Hirai, T., Nagai, S., Chin, K. and Mishima, M. (2017) Importance of Se-rial Changes in Biomarkers in Idiopathic Pulmonary Fibrosis. ERJ Open Research, 3, 1-8. https://doi.org/10.1183/23120541.00019-2016
|
[22]
|
Wakamatsu, K., Nagata, N., Kumazoe, H., Oda, K., Ishimoto, H., Yoshimi, M., Takata, S., Hamada, M., Koreeda, Y., Takakura, K., Ishizu, M., Hara, M., Ise, S., Izumi, M., Akasaki, T., Maki, S., Kawabata, M., Mukae, H. and Kawasaki, M. (2017) Prognostic Value of Serial Serum KL-6 Measurements in Patients with Idiopathic Pulmonary Fibrosis. Respiratory Investigation, 55, 16-23. https://doi.org/10.1016/j.resinv.2016.09.003
|
[23]
|
Qiu, M., Chen, Y. and Ye, Q. (2018) Risk Factors for Acute Ex-acerbation of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. The Clinical Respiratory Journal, 12, 1084-1092. https://doi.org/10.1111/crj.12631
|
[24]
|
Kohno, N., Awaya, Y., Oyama, T., Yamakido, M., Akiyama, M., Inoue, Y., Yokoyama, A., Hamada, H., Fujioka, S. and Hiwada, K. (1993) KL-6, a Mucin-Like Glycoprotein, in Bronchoalveolar Lavage Fluid from Patients with Interstitial Lung Disease. The American Review of Respiratory Disease, 148, 637-642.
https://doi.org/10.1164/ajrccm/148.3.637
|
[25]
|
Mulugeta, S., Nureki, S.-I. and Beers, M. F. (2015) Lost after Translation: Insights from Pulmonary Surfactant for Understanding the Role of Alveolar Epithelial Dysfunction and Cel-lular Quality Control in Fibrotic Lung Disease. American Journal of Physiology. Lung Cellular and Molecular Physiolo-gy, 309, L507-L525.
https://doi.org/10.1152/ajplung.00139.2015
|
[26]
|
Greene, K.E., King, T.E., Kuroki, Y., Bucher-Bartelson, B., Hun-ninghake, G.W., Newman, L.S., Nagae, H. and Mason, R.J. (2002) Serum Surfactant Proteins-A and -D as Biomarkers in Idiopathic Pulmonary Fibrosis. The European Respiratory Journal, 19, 439-446. https://doi.org/10.1183/09031936.02.00081102
|
[27]
|
Kinder, B.W., Brown, K.K., McCormack, F.X., Ix, J.H., Ker-vitsky, A., Schwarz, M.I. and King, T.E. (2009) Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis. Chest, 135, 1557-1563.
https://doi.org/10.1378/chest.08-2209
|
[28]
|
Wang, K., Ju, Q., Cao, J., Tang, W. and Zhang, J. (2017) Impact of Se-rum SP-A and SP-D Levels on Comparison and Prognosis of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Medicine, 96, e7083.
https://doi.org/10.1097/MD.0000000000007083
|
[29]
|
Nishikiori, H., Chiba, H., Ariki, S., Kuronuma, K., Otsuka, M., Shiratori, M., Ikeda, K., Watanabe, A., Kuroki, Y. and Takahashi, H. (2014) Distinct Compartmentalization of SP-A and SP-D in the Vasculature and Lungs of Patients with Idiopathic Pulmonary Fibrosis. BMC Pulmonary Medicine, 14, Article No. 196.
https://doi.org/10.1186/1471-2466-14-196
|
[30]
|
Maher, T.M., Oballa, E., Simpson, J.K., Porte, J., Habgood, A., Fahy, W.A., Flynn, A., Molyneaux, P.L., Braybrooke, R., Divyateja, H., Parfrey, H., Rassl, D., Russell, A.-M., Saini, G., Renzoni, E.A., Duggan, A.-M., Hubbard, R., Wells, A.U., Lukey, P.T., Marshall, R.P. and Jenkins, R.G. (2017) An Epithelial Biomarker Signature for Idiopathic Pulmonary Fibrosis: An Analysis from the Multicentre PROFILE Cohort Study. The Lancet Respiratory Medicine, 5, 946-955.
https://doi.org/10.1016/S2213-2600(17)30430-7
|
[31]
|
Doubková, M., Karpíšek, M., Mazoch, J., Skřičková, J. and Doubek, M. (2016) Prognostic Significance of Surfactant Protein A, Surfactant Protein D, Clara Cell Protein 16, S100 Protein, Trefoil Factor 3, and Prostatic Secretory Protein 94 in Idiopathic Pulmonary Fibrosis, Sarcoidosis, and Chronic Pulmonary Obstructive Disease. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of WASOG, 33, 224-234.
|
[32]
|
Morais, A., Beltrão, M., Sokhatska, O., Costa, D., Melo, N., Mota, P., Marques, A. and Delgado, L. (2015) Serum Metalloproteinases 1 and 7 in the Diagnosis of Idiopathic Pulmonary Fibrosis and Other Interstitial Pneu-monias. Respiratory Medicine, 109, 1063-1068. https://doi.org/10.1016/j.rmed.2015.06.003
|
[33]
|
Tzouvelekis, A., Herazo-Maya, J. D., Slade, M., Chu, J.-H., Deiuliis, G., Ryu, C., Li, Q., Sakamoto, K., Ibarra, G., Pan, H., Gulati, M., Antin-Ozerkis, D., Herzog, E.L. and Kaminski, N. (2017) Validation of the Prognostic Value of MMP-7 in Idiopathic Pulmonary Fibrosis. Respirology (Carlton, Vic.), 22, 486-493. https://doi.org/10.1111/resp.12920
|
[34]
|
Richards, T.J., Kaminski, N., Baribaud, F., Flavin, S., Brodmerkel, C., Horowitz, D., Li, K., Choi, J., Vuga, L.J., Lindell, K.O., Klesen, M., Zhang, Y. and Gibson, K.F. (2012) Peripheral Blood Proteins Predict Mortality in Idiopathic Pulmonary Fi-brosis. American Journal of Respiratory and Critical Care Medicine, 185, 67-76.
https://doi.org/10.1164/rccm.201101-0058OC
|
[35]
|
Kreuter, M., Lee, J.S., Tzouvelekis, A., Oldham, J.M., Molyneaux, P.L., Weycker, D., Atwood, M., Kirchgaessler, K.U. and Maher, T.M. (2021) Monocyte Count as a Prog-nostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 204, 74-81.
https://doi.org/10.1164/rccm.202003-0669OC
|
[36]
|
Nathan, S.D., Reffett, T., Brown, A.W., Fischer, C.P., Shlobin, O.A., Ahmad, S., Weir, N. and Sheridan, M.J. (2013) The Red Cell Distribution width as a Prognostic Indicator in Idio-pathic Pulmonary Fibrosis. Chest, 143, 1692-1698.
https://doi.org/10.1378/chest.12-1368
|
[37]
|
Chen, Y., Cai, J., Zhang, M. and Yan, X. (2022) Prognostic Role of NLR, PLR and MHR in Patients with Idiopathic Pulmonary Fibrosis. Frontiers in Immunology, 13, Article ID: 882217. https://doi.org/10.3389/fimmu.2022.882217
|
[38]
|
Zinellu, A., Paliogiannis, P., Sotgiu, E., Mellino, S., Mangoni, A.A., Zinellu, E., Negri, S., Collu, C., Pintus, G., Serra, A., Pistuddi, A.M., Carru, C., Pirina, P. and Fois, A.G. (2020) Blood Cell Count Derived Inflammation Indexes in Patients with Idiopathic Pulmonary Fibrosis. Lung, 198, 821-827. https://doi.org/10.1007/s00408-020-00386-7
|
[39]
|
Nathan, S.D., Mehta, J., Stauffer, J., Morgenthien, E., Yang, M., Limb, S.L. and Bhorade, S. (2021) Changes in Neutrophil-Lymphocyte or Platelet-Lymphocyte Ratios and Their Associ-ations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 10, Article No. 1427. https://doi.org/10.3390/jcm10071427
|
[40]
|
Ruta, V.M., Man, A.M., Alexescu, T.G., Motoc, N.S., Tarmure, S., Ungur, R.A., Todea, D.A., Coste, S.C., Valean, D. and Pop, M.C. (2020) Neutrophil-to-Lymphocyte Ratio and Systemic Immune-Inflammation Index-Biomarkers in Interstitial Lung Disease. Medicina (Kaunas), 56, Article No. 381. https://doi.org/10.3390/medicina56080381
|